Angiodynamics (ANGO) Cash from Investing Activities (2010 - 2026)

Angiodynamics (ANGO) has 17 years of Cash from Investing Activities data on file, last reported at -$1.3 million in Q2 2026.

• Quarterly Cash from Investing Activities rose 51.58% year-over-year to -$1.3 million in Q2 2026, while the trailing twelve-month figure through May 2026 was -$5.9 million (up 41.55% YoY) and the FY2026 annual result came in at -$5.9 million, up 41.55% from the prior year.
• Cash from Investing Activities advanced to -$1.3 million in Q2 2026, from -$1.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $98.4 million in Q3 2023 to a low of -$3.8 million in Q2 2022.
• A 5-year average of $5.1 million and a median of -$2.1 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 2852.85% — and 2025, when it slumped 110.85%.
• Tracing ANGO's Cash from Investing Activities over 5 years: stood at -$2.5 million in 2022, then advanced by 28.17% to -$1.8 million in 2023, then retreated by 9.37% to -$2.0 million in 2024, then advanced by 17.34% to -$1.6 million in 2025, then rose by 21.65% to -$1.3 million in 2026.
• The last three Cash from Investing Activities figures came in at -$1.3 million (Q2 2026), -$1.5 million (Q1 2026), and -$1.6 million (Q4 2025), per Business Quant data.